This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amylyx (AMLX) Secures the FDA's Approval for ALS Drug
by Zacks Equity Research
Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.
Sanofi (SNY) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $38, marking a -0.45% move from the previous day.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
by Zacks Equity Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights Broadcom, Comcast, Equinor, Intuit and Sanofi
by Zacks Equity Research
Broadcom, Comcast, Equinor, Intuit and Sanofi are part of The Zacks top Analyst Blog.
Top Research Reports for Broadcom, Comcast & Equinor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Comcast Corp. (CMCSA) and Equinor ASA (EQNR).
Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
by Zacks Equity Research
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
by Zacks Equity Research
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors
by Zacks Equity Research
The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
by Zacks Equity Research
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID
by Zacks Equity Research
Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.
AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication
by Zacks Equity Research
The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.
Sanofi (SNY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Sanofi (SNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
by Zacks Equity Research
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $40.59 in the latest trading session, marking a -0.56% move from the prior day.
Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia
by Zacks Equity Research
The CHMP recommends authorizing Sanofi's (SNY) Enjaymo as a treatment for hemolytic anemia in patients with cold agglutinin disease (CAD). The CHMP endorses SNY's RSV vaccine for use in infants.
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
by Zacks Equity Research
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $41.49 in the latest trading session, marking a +1.69% move from the prior day.
Sanofi (SNY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $39.59, marking a -1.22% move from the previous day.
Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
by Kinjel Shah
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.